I
n spite of the available number of antihypertensive agents, blood pressure (BP) management remains difficult for many patients and leads to a progressive end-organ dysfunction, suggesting the need for alternative therapeutic options.
The bioactive lipid S1P (sphingosine-1-phosphate) has emerged as an important regulator of vascular development and stability, 1,2 angiogenesis, 3 permeability, 4 and ex vivo vascular tone. 5, 6 These cardiovascular functions are mediated by 3 out of the 5 G protein-coupled receptors, named S1PR1-3 (S1P receptor 1-3). In the endothelium, S1PR1 is highly abundant, whereas S1PR3 is expressed at a lower level.
4 S1P strongly activates endothelial nitric oxide synthase (eNOS)-derived nitric oxide (NO) production, 5 comparable in magnitude to VEGF and bradykinin. 7 Recently, Cantalupo et al discovered an important role of endothelial-derived S1P in blood flow and pressure regulation through the autocrine S1PR1/eNOS signaling and demonstrated that upregulation of endothelial-derived S1P prevents the onset of hypertension. 6 Furthermore, SEW2871 (5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-[3-(trifluoromethyl)phenyl]1,2,4-oxadiazole), an agonist of S1PR1, restores normal BP in hypertensive mice 6 and prevents the onset pathological cardiac hypertrophy, 8 revealing important cardiovascular protective functions of the S1PR1 signaling. S1PR3 is expressed in vascular smooth muscle cells (VSMC) of various vascular beds 9, 10 and along with S1PR2 induce vasoconstriction via Gq-coupled Ca 2+ /IP 3 and G13-coupled RhoA/ Rho kinase pathway. 11, 12 On the contrary, endothelial S1PR3 mediates high-density lipoprotein-bound S1P-induced vasodilation of thoracic aorta ex vivo via eNOS-derived NO production. 13 Consistently, in vivo, S1P triggers a small and transient decrease in BP in wild-type but not in S1pr3 −/− mice, 14 suggesting an involvement of S1PR3 in the BP effects of S1P.
Although the roles of S1PR1-3 have been examined during vascular development, 2 the impacts of S1PR1,3 signaling on vascular tone and BP regulation remain poorly understood.
Abstract-Nitric oxide is one of the major endothelial-derived vasoactive factors that regulate blood pressure (BP), and the bioactive lipid mediator S1P (sphingosine-1-phosphate) is a potent activator of endothelial nitric oxide synthase through G protein-coupled receptors. Endothelial-derived S1P and the autocrine/paracrine activation of S1PR (S1P receptors) play an important role in preserving vascular functions and BP homeostasis. Furthermore, FTY720 (fingolimod), binding to 4 out of 5 S1PRs recently approved by the Food and Drug Administration to treat autoimmune conditions, induces a modest and transient decrease in heart rate in both animals and humans, suggesting that drugs targeting sphingolipid signaling affect cardiovascular functions in vivo. However, the role of specific S1P receptors in BP homeostasis remains unknown. The aim of this study is to determine the role of the key vascular S1P receptors, namely, S1PR1 and S1PR3, in BP regulation in physiological and hypertensive conditions. The specific loss of endothelial S1PR1 decreases basal and stimulated endothelial-derived nitric oxide and resets BP to a higher-than-normal value. Interestingly, we identified a novel and important role for S1PR1 signaling in flow-mediated mechanotransduction. FTY720, acting as functional antagonist of S1PR1, markedly decreases endothelial S1PR1, increases BP in control mice, and exacerbates hypertension in angiotensin II mouse model, underlining the antihypertensive functions of S1PR1 signaling. Our study identifies S1P-S1PR1-nitric oxide signaling as a new regulatory pathway in vivo of vascular relaxation to flow and BP homeostasis, providing a novel therapeutic target for the treatment of hypertension. Our study shows that S1PR1 plays a predominant role in BP homeostasis, via NO-mediated vasodilation in response to S1P, and particularly to flow, unveiling a novel role of S1PR1 as mechanotransducer. S1PR3 is mainly responsible for S1P-induced vasoconstriction and myogenic tone. FTY720 (fingolimod), a prodrug that targets 4 of the 5 S1P receptors, S1PR1, S1PR3, S1PR4, and S1PR5, 15 with highest affinity for S1PR1, 16 was approved for use by the Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis. 15, 17 When administered chronically, FTY720 induces the internalization and degradation of S1PR1 and, hence, defined functional antagonist. 18 A major biological function of FTY720 is to block the egress of lymphocytes from lymphoid tissues. 19 The activation of the receptors S1P1 in the cardiovascular system accounts for the transient effects of FTY720 on heart rate, the atrioventricular conduction, and the lasting effect on BP. 17, 20 Because our findings suggested a critical role for S1PR1 signaling in the BP homeostasis, we also investigated the impact of chronic FTY720 treatment of vascular tone and BP homeostasis. FTY720 treatment increased BP in control mice, exacerbated hypertension, and impaired endothelial-dependent vasodilation. These data corroborate the protective role of S1P signaling in BP regulation. Our study reveals for the first time a critical role of S1PR1-NO signaling in flow-mediated vasodilation and BP homeostasis and underlines potential deleterious effects of FTY720 on the vascular functions. Furthermore, it identifies specific roles of S1PR1 and S1PR3 in the vasomotor reactivity of resistance arteries to S1P, flow, and intraluminal pressure.
Methods

Animals
S1pr1 floxed mice (S1pr1 f/f ) 21 were crossed to VE-cadherin-Cre-ER T2 to generate mice lacking S1PR1 specifically in endothelial cells (EC; Figure 1 . The loss of S1PR1 (sphingosine-1-phosphate receptor 1), but not S1PR3, induces high blood pressure and impairs flowmediated vasodilation. Systolic blood pressure (SBP) in (A) ECKO-S1pr1 and S1pr1 f/f mice, measured with tail-cuff system. n≥8 mice/ group. ECKO-S1pr1 and S1pr1 f/f MA were assessed by pressure myograph system for (Ba) S1P-induced vasodilation, n≥5 mice/group (n≥8 MA/group); (Bb) acetylcholine (Ach)-induced vasodilation, n≥7 mice/group (n≥14 MA/group); (Bc) flow-mediated vasodilation, n≥5 mice/group (n≥9 MA/group). (Ca) Δ decrease of the inner diameter induced by l-N G -nitroarginine methyl ester (L-NAME) and (Cb) Ach response after incubation of ECKO-S1pr1 and S1pr1 f/f with L-NAME, n≥4 mice /group (n≥8 MA/group). Nitrite (NOx) levels were measured in (Da) plasma of ECKO-S1pr1 and S1pr1 f/f mice by using the Griess reaction, n≥4 mice/group, and (Db) in mesenteric arteries (MA) from the same groups by using a fluorimetric assay, n=5 mice/group. E, SBP in S1pr3 −/− and littermate wild-type (WT) mice, n≥8 mice/group measured with tail cuff system. S1pr3 −/− and WT MA were assessed for vasodilation to (Fa) S1P, n≥5 mice/group (n≥7 MA/group); (Fb) Ach, n≥7 mice/group (n≥14 MA/group); and (Fc) flow, n≥5 mice/group (n≥9 MA/group). Fd, S1pr3
−/− and WT plasma nitrite (NOx) were assessed by Griess reaction, n=7 mice/group. Data were expressed as the mean±SEM. *P<0.05; **P<0.01; and ***P<0.001 compared with control mice. Statistical significance was determined by unpaired t test or 2-way analysis of variance (ANOVA).
ECKO-S1pr1). These mice have been backcrossed with C57BL/6 for >8 generations. To excise the floxed-S1pr1 gene, mice were treated daily with tamoxifen 3 mg/kg for five consecutive days at the age of 6 to 8 weeks. S1pr3 −/− mice were generated as previously described. 2 Heterozygous S1p3 mice were bred to generate S1pr3 −/− and control littermates used for this study. The C57BL/6 mice used for the experiments with FTY720 in normotension and hypertension are generated in our laboratory by breeding C57BL/6 mice. All of the studies were performed according to protocols approved by the Weill Cornell Institutional Animal Care and Use Committee.
Statistical Analysis
Data were expressed as mean±SEM. One-way or 2-way analyses of variance were used for all statistical analyses except where Student's t test analysis was used. Differences were considered statistically significant when P<0.05. All the tests were 2-sided. GraphPad Prism software (version 6.0; GraphPad Software, San Diego, CA) was used for all the statistical analysis.
Detailed description of the Materials and Methods is available in the online-only Data Supplement.
Results
Endothelial S1PR1, but Not S1PR3, Mediates S1P-and Flow-Induced Vascular Tone and BP
Homeostasis via eNOS Activation
We have previously demonstrated that the inhibition of S1PR1 with W146 suppressed flow-mediated vasodilation, whereas the administration of SEW2871 in hypertensive mice strongly reduced BP to normal values, 6 suggesting a protective role of S1PR1 in hypertension. To directly assess the role of S1PR1 in vascular tone and BP regulation, we used a conditional knockout mouse model lacking S1PR1 specifically in EC (ECKO-S1pr1) 22 and measured BP in vivo and vasomotor reactivity of mesenteric arteries (MA) ex vivo by using the pressure myograph system. 6 At baseline, ECKO-S1pr1 systolic BP (SBP) was higher than normal values ( Figure 1A ). S1P-mediated vasodilation was markedly reduced in ECKO-S1pr1 MA (Figure 1Ba ), whereas acetylcholine (Ach)-induced vasodilation was preserved (Figure 1Bb ), suggesting that these signaling pathways are not interdependent. Interestingly, flow-induced vasodilation was blunted in ECKO-S1pr1 MA, revealing a novel role for S1PR1 in mechanotransduction signaling (Figure 1Bc ). An important mediator of S1P and flow-induced vasorelaxation is eNOS-derived NO ( Figure S1A through S1D in the online-only Data Supplement). ECKO-S1pr1 mice showed a reduction in basal and Ach-stimulated NO production in MA (Figure 1Ca and 1Cb), in NOx plasma levels ( Figure 1Da ) compared with control mice, and significantly lower NOx levels in MA (Figure 1Db ).
On the contrary, the loss of S1PR3 did not alter BP in vivo ( Figure 1E ), the vasorelaxation of MA in response to S1P (Figure 1Fa ), Ach and flow (Figure 1Fb and 1Fc) , and NOx plasma levels (Figure 1Fd ), suggesting that S1PR3 is dispensable to mediate endothelial regulation of vascular tone in resistance arteries.
These findings reveal a predominant role of S1PR1 in S1P-and flow-mediated vascular tone and BP homeostasis.
S1PR3 Controls Vasoconstriction to S1P and Pressure of Resistance Arteries
Vascular studies showed that S1P-mediated vasoconstriction was markedly increased in ECKO-S1pr1 MA (Figure 2A ), most likely imputable to the lack of S1PR1-eNOS-NO pathway activation in the endothelium. On the contrary, the vasoconstriction of S1pr3 −/− MA in response to S1P ( Figure 2B ) Figure 2 . The lack of S1PR3 (sphingosine-1-phosphate receptor 3) specifically decreases the vasoconstriction in response to S1P and pressure in normotensive mesenteric arteries (MA). Concentration-response curves of ECKO-S1pr1, S1pr3
, and control MA in response to (A and B) S1P-induced vasoconstriction, n≥7 mice/group (n≥7 MA/group); (Ca and Da) myogenic tone (%), and (Cb, Db) passive tone in response to intraluminal pressure increase, n≥8 mice/group (n≥11 MA/group), and (E and F) phenylephrine (PE)-mediated vasoconstriction, n≥5 mice/group (n≥9 MA/group). Data were expressed as the mean±SEM. **P<0.01 and ***P<0.001 compared with control mice. Statistical significance was determined by 2-way analysis of variance (ANOVA).
and intraluminal pressure (Figure 2Ca and 2Da) was significantly reduced, suggesting a direct and novel role for S1PR3 in myogenic tone regulation. ECKO-S1pr1, but not S1pr3 −/− MA, also showed an increased internal diameter, index of outward remodeling of the vessel (Figure 2Cb ). Finally, phenylephrine (PE)-induced vasoconstriction was not altered in ECKOS1pr1 and S1p3 −/− MA compared with the control (Figure 2E  and 2F) . Altogether, these data indicate that VSMC S1PR3 plays a major role in regulating MA tone in response to S1P and pressure, while S1PR1 contributes mainly to the endothelial-dependent regulation of vascular tone and structure.
S1PR1, but Not S1PR3 Signaling, Maintains Low BP in Physiological and Pathological Conditions
Although the role of S1PR1 has been elegantly studied in the vasculature during embryogenesis, 2 its role in BP Figure 3 . S1PR1 (sphingosine-1-phosphate receptor 1) signaling exerts antihypertensive and vasculoprotective functions. A, Systolic blood pressure (SBP) was measured with tail-cuff system in S1pr1 f/f and ECKO-S1pr1 mice before and after angiotensin II (AngII)-osmotic pump implantation twice/week for 28 days. ECKO-S1pr1 and S1pr1 f/f mesenteric arteries (MA) were assessed for vascular reactivity in response to (B) acetylcholine (Ach), n=5 mice/group (n≥8 MA/group); (Ca) changes in flow, n=5 mice/group (n≥6 MA/ group); (Cb) myogenic tone (%), n=5 mice/group (n≥7 MA/group); and (Da, b) phenylephrine (PE), n=5 mice/group (n≥6 MA/group). Ea, Immunoblot analysis for S1PR1 in thoracic aortas of normotensive and hypertensive wild-type (WT) mice and (Eb) relative quantification of S1PR1 expression to β-actin (n=5 mouse aorta/group). Ec, S1P-induced vasodilation in normotensive and hypertensive WT MA, n=4 mice/group (n=4 MA/group). F, Immunofluorescent staining for S1PR1 (red) and IB4 (isolectin; green) in normotensive and hypertensive WT, ECKO-S1pr1 MA. Nuclei are stained with DAPI (blue). Data were expressed as mean±SEM. homeostasis in the adults is largely unknown. ECKO-S1pr1 mice showed higher BP than S1pr1 f/f at baseline, as well as after angiotensin II (AngII) chronic infusion ( Figure 3A) , underlying antihypertensive functions of S1PR1 signaling. Ach-induced vasodilation was impaired to the same extent in hypertensive and normotensive ECKO-S1pr1 and S1pr1 f/f MA, indicating the same degree of endothelial dysfunction ( Figure 3B) . Interestingly, the vasorelaxation to flow was already blunted in ECKO-S1pr1 MA at baseline and was no further affected by AngII treatment (Figure 3Ca ), suggesting that S1PR1 specifically mediates the vasodilation in response to flow upstream the NO pathway. At baseline, ECKO-S1pr1 MA vascular tone was augmented at baseline (Figure 3Cb) , whereas PE-induced vasoconstriction was not affected (Figure 3Da and 3Db) .
Next, we assessed S1PR1 levels in hypertension. Western blot analysis of aortas and relative quantification (Figure 3Ea and 3Eb) and immunofluorescent staining of MA (Figure 3Ec ) showed that S1PR1 expression was not altered in hypertension. However, S1P-induced vasodilation was significantly reduced in MA from AngII-treated mice ( Figure 3F ), most likely because of the impairment in the downstream NO production during hypertension. 23 Importantly, the loss of S1PR3 did not alter the onset of hypertension ( Figure S2A ), as well as the vasodilation in response to Ach, flow, and S1P in hypertensive MA versus wild-type ( Figure S2Ba through S2Bc). On the contrary, vasoconstrictions to PE, pressure, and S1P were markedly reduced ( Figure S2Ca through S2Cc), indicating a prevailing role of S1PR3 in the VSMC versus EC functions.
Collectively, these data demonstrate that S1PR1 signaling is a key pathway in BP homeostasis, and when genetically ablated, BP is reset to a higher-then-normal value in both physiological and pathological conditions.
Chronic Administration of FTY720 Increases BP in Normotensive Mice and Exacerbates Hypertension Induced by Chronic Infusion of AngII
The antihypertensive effects of SEW2871 6 and the increase in SBP after genetic depletion of S1pr1 in the endothelium raises questions of the effects of FTY720 on the cardiovascular system, especially considering that when given chronically, FTY720 acts as functional antagonist of S1PR1. 24, 25 In patients, FTY720 induces bradycardia within 6 hours after the first dose 17, 26 and a slight increase of BP (≈2-5 mm Hg) with chronic treatment. 17, 20 In rodents, the administration of FTY720 for a period of 10 days significantly raised the BP in rats in a dose-dependent manner, 27 while a single dose of FTY720 further increased the BP of hypertensive spontaneously hypertensive rats at 24 hours postadministration, 28 suggesting that drugs inhibiting S1PR1 signaling may be deleterious in hypertension.
Thus, we sought to investigate in details the effect of FTY720 on vascular tone and BP regulation in normotensive and hypertensive mice. Chronic administration of FTY720 (0.3 mg/kg, every other day for 5 weeks) in C57BL/6 transiently . Chronic administration of FTY720 (fingolimod) 0.3 mg/kg increases systolic blood pressure (SBP) in normotensive mice and induces vascular dysfunction. Male C57/Bl6 mice were treated with FTY720 0.3 mg/kg or vehicle PO for 35 days, and (A) SBP was measured with tail-cuff system twice/week, n=5 mice/group. B, Immunofluorescent staining for S1PR1 (sphingosine-1-phosphate receptor 1; red) and IB4 (isolectin; green) in mesenteric arteries (MA) isolated from FTY720 (0.3 mg/kg) or vehicle-treated wild-type (WT) mice. Nuclei were stained with DAPI (blue). MA from FTY720 0.3 mg/kg or vehicle-treated group were assessed for vascular reactivity in response to (Ca) acetylcholine (Ach), n≥5 mice/group (n≥10 MA/group); (Cb) S1P, n≥5 mice/group, (n≥5 MA/group); and (Cc) stepwise increase in flow, n≥5 mice/group (n≥9 MA/group). Cd, Nitrite (NOx) plasma levels were quantified with Griess reaction method. n≥5 mice/ group. Vasoconstriction in response to (Da) phenylephrine (PE), n≥5 mice/group (n≥10 MA/group); (Db) S1P, n≥5 mice/group (n≥5 MA/ group); (Dc) increase in intraluminal pressure and expressed as percent of myogenic tone calculated as described in Methods, n≥5 mice/ group (n≥7 MA/group). Dd, Endothelium-independent vasodilation to sodium nitroprussiate (SNP, an NO-donor), n≥4 mice/group (n≥4 MA/group). Data were expressed as the mean±SEM. *P<0.05, **P<0.01, and ***P<0.001 compared with vehicle-treated group. Statistical significance was determined by 2-way analysis of variance (ANOVA) or unpaired t test.
increased SBP at day 7 and constantly raised SBP from day 10 up to ≈130 mm Hg ( Figure 4A ). The levels of S1PR1 in MA from mice treated with FTY720 were undetectable in the endothelium and in the adventitia compared with the vehicletreated group ( Figure 4B) .
The endothelial-dependent vasodilation in response to Ach, S1P, and flow was markedly reduced in MA from FTY720-treated mice (Figure 4Ba through 4Bc) , as well as plasma levels of NOx (Figure 4Bd) . Although the vasoconstriction induced by PE and pressure was not different, S1P-induced contraction was significantly increased (Figure 4Ca through  4Cc) , most likely because of the downregulation of endothelial S1PR1. Surprisingly the vasodilation induced by sodium nitroprussiate, a NO donor, was also impaired (Figure 4Cd ), suggesting that long-term FTY720 treatment impairs the endothelial-dependent and -independent vasodilation.
Next, we assessed the therapeutic effects of FTY720 treatment in hypertension. Chronic administration of FTY720 (0.30 mg/kg) in AngII-infused mice induced a significant and prolonged increase in SBP compared with vehicle-treated mice ( Figure 5A ). The expression of S1PR1 was not detectable by immunofluorescence in MA from FTY720-treated mice ( Figure 5B ). Functionally, FTY720 treatment markedly reduced S1P-induced vasodilation, corroborating the functional antagonism of FTY720 on S1PR1 ( Figure 5C ).
Ach-mediated vasodilation of hypertensive MA was significantly reduced by FTY720 ( Figure 5D ), whereas no differences were observed in response to flow ( Figure 5C ), most likely because it was already suppressed in vehicle-treated MA. Furthermore, FTY720 did not alter VSMC contractility in response to PE, S1P, and intraluminal pressure ( Figure S3 ), as well as MA morphometry (Figure S3Cb) .
At a lower dose, FTY720 (0.15 mg/kg) did not alter the onset of hypertension ( Figure S4A ). Although S1P-mediated vasodilation was significantly reduced, the response to Ach of MA was improved (Figure S4Ba and S4Bb) . However, no differences were observed in response to changes in flow ( Figure  S4Bc) , pressure, PE, and S1P ( Figure S4Ca through S4Cc) .
Altogether, these findings suggest that long-term treatment of FTY720 at 0.3 mg/kg exacerbates AngII-induced hypertension in vivo, in part through the downregulation of endothelial S1PR1 signaling, underlining the importance of this pathway in maintaining vascular homeostasis ( Figure 6 ).
Discussion
Hypertension, the leading cause for myocardial infarction, heart failure, and stroke, 29 is multifactorial and highly complex. Despite current therapies, BP management does not reach a satisfactory outcome in all the patients, suggesting the need for alternative therapeutic targets and a better Figure 5 . FTY720 (fingolimod) 0.3 mg/kg exacerbates the hypertension in angiotensin II (AngII)-treated mice and impairs the response to S1P (sphingosine-1-phosphate). C57BL/6 mice infused with AngII were chronically treated with FTY720 (0.3 mg/kg) or vehicle PO and (A) systolic blood pressure (SBP) monitored by using tail-cuff system, n=6 mice/group. B, Immunofluorescent staining for S1PR1 (S1P receptor 1; red) and IB4 (isolectin; green) of mesenteric arteries (MA) isolated from hypertensive wild-type (WT) mice treated with FTY720 (0.3 mg/kg) or vehicle. Nuclei (blue) were stained with DAPI. MA from both groups were assessed for vascular reactivity in response to (C) S1P, n=6 mice/group (n≥6 MA/group); (D) acetylcholine (Ach), n=6 mice/group (n≥6 MA/group); and (E) stepwise increase in flow, n=6 mice/group (n≥6 MA/group). F, NOx plasma levels were quantified with Griess reaction method. n≥7 mice/group. Data were expressed as the mean±SEM. *P<0.05 and ***P<0.001 compared with vehicle-treated group or unless otherwise indicated. Statistical significance was determined by 1-or 2-way analysis of variance (ANOVA).
understanding of underlying mechanisms. The results of this study reveal S1PR1 signaling as a necessary pathway to preserve BP homeostasis. Indeed, genetic and pharmacological (FTY720) depletion of S1PR1 impairs vascular functions and increases BP. Furthermore, our data identify a novel role of S1PR1 in mediating the response of resistance arteries to flow, thus, acting as mechanoreceptor.
Recently, we reported that endothelial derived S1P has a great impact on systemic BP regulation via S1PR1-S1P-eNOS autocrine signaling. 6, 11, 22 Shear stress exerted by flowing blood induces the production and release of S1P by the endothelium, 30 contributing to the physiological activation of S1PR1 signaling in the vasculature. 6 Pharmacological inhibition of S1PR1 in MA significantly reduced flow-mediated vasodilation, 6, 11 and lack of S1PR1 in EC in vitro and thoracic aorta in vivo reduced eNOS activation in response to shear stress, 22 implicating S1PR1 signaling in the flow-mediated vasodilation upstream of NO production.
Shear stress induces the release of vasodilatory factors, of which NO is the predominant mediator of the vasorelaxation induced by flow. 31, 32 Despite the broad effort to identify the cellular mechanisms of mechanotransduction, how mechanical forces are translated in biological and biochemical responses remain unclear. Multiple mechanotransduction signaling have been suggested, including ion channels, 33, 34 40 which, in turn, can bind to P2Y 2 receptors in autocrine/paracrine manner and trigger the downstream activation of AKT-eNOS signaling. 39 In addition to ATP, shear stress also stimulates endothelial release of S1P.
30 S1PR1 was shown to be necessary for flow-mediated primary vascular network formation in the retina, alignment of ECs in response to flow-mediated Akt and eNOS activation, 22 and vasodilation of resistance arteries in response to flow, 6, 11 suggesting its critical involvement in biomechanical signaling in the endothelium.
Here, we demonstrated that the loss of endothelial S1PR1 or FTY720 treatment abolished flow-dependent vasorelaxation, reduced plasmatic levels of NOx, and reset system BP to a higher-than-normal value, providing compelling and direct evidence of the importance of S1PR1 as critical mechanosensing pathway in BP homeostasis. Additionally, endothelial S1R1 also preserves vascular structure in adult mice, as ECKO-S1pr1 MA showed an outward remodeling. This is not surprising because global S1pr1-KO mice are embryonically lethal because of a defect in smooth muscle cell coverage and vascular maturation. 1 Initial studies demonstrated that vasoconstriction of basilar arteries in response to S1P is mainly mediated by S1PR3 and not S1PR2. 9, 10 However, the lack of S1PR2 does not alter systemic BP, 41 indicating a minor role of this receptor. A recent study from Hoefer et al 42 reported S1PR2 as key regulator of myogenic tone in MA during heart failure conditions. Our data demonstrated an important and specific role of S1PR3 in vascular tone induced by S1P and pressure, although its loss did not affect the systemic BP in normotensive and hypertensive conditions. BP is not affected by the deletion of either S1pr2 41 or S1pr3, possibly because of a compensatory mechanism by either one of these receptors.
The loss of S1PR3 did not affect the vasorelaxation induced by low concentrations of S1P. These data suggest a prevailing function of VSMC versus EC S1PR3 in vascular tone regulation. This finding is not in contradiction with the study published few years ago by Noefer et al demonstrating that S1P-and high-density lipoprotein-induced vasodilation was reduced in the thoracic aorta rings from S1pr3 −/− mice. 13 In this study, the authors used capacitance artery (thoracic aorta), whereas here we used resistance arteries MA from S1pr3 −/− mice, more relevant to BP regulation. It is likely that endothelial S1PR3 plays an important role in the high-density lipoprotein-bound S1P-mediated atheroprotective functions in capacitance arteries, whereas in resistance arteries, the smooth muscle S1PR3 controls vascular tone.
Previous studies reported that locally produced S1P is important in myogenic tone regulation, [42] [43] [44] in part, via S1PR2 activation. 42 Here, we unveiled an important role also for S1PR3 in myogenic tone regulation.
Finally, FTY720 treatment markedly raises BP in normotensive and hypertensive mice also underlie the importance of S1P signaling in maintaining BP homeostasis. Although it is difficult to tease out mechanisms accountable for the Figure 6 . Endothelial S1PR1 (sphingosine-1-phosphate receptor 1) is a key regulator of blood flow and pressure. In addition to mediate S1P-induced vasodilation, this study revealed an important role of endothelial S1PR1 in systemic blood pressure (BP) regulation and biomechanical signaling and unveils potential cardiovascular side effects of FTY720 (fingolimod), S1PR1 functional antagonist. The increase in flow induces the release of S1P by the endothelium, which activates S1PR1 through an autocrine/paracrine manner, leading to endothelial nitric oxide synthase (eNOS)-derived NO production and vasodilation. On the contrary, S1PR3 signaling plays a prevalent role in regulating the tone of the smooth muscle layer in response to S1P and intraluminal pressure increase but has no effect on SBP. Chronic administration of FTY720 downregulates S1PR1 in the endothelium and adventitia of the mesenteric arteries (MA) and markedly impairs vascular functions, leading to systemic increase of BP. EC indicates endothelial cell; and VSMC, vascular smooth muscle cell.
FTY720-induced elevation in BP in vivo, in ex vivo studies of resistance arteries FTY720 reduced the vasodilation induced by S1P and Ach in the endothelium, as well as VSMC relaxation in response to sodium nitroprussiate, an NO donor. Our data suggest that long-term administration of FTY720 impairs not only the endothelial but also smooth muscle cells functions by impairing the NO-induced activation of guanylyl cyclase and cGMP-mediated vasorelaxation. S1P vasodilation is imputable to both downregulation of S1PR1 by FTY720 and NO-cGMP signaling. Our data are also in agreement with a previous study from Spijkers et al 28 showing an increase in BP of spontaneously hypertensive rats when treated with 1 dose of FTY720 and the recent study of Fryer et al 27 demonstrating a dose-dependent increase in BP in rats after chronic FTY720 administration.
The finding that S1PR1 signaling plays an important role in the mechanotransduction of the endothelial shear stress to impact vascular tone and BP homeostasis is novel and of great significance for better understanding the molecular mechanisms of the endothelial dysfunction not only in the pathogenesis of hypertension but also in other cardiovascular diseases where endothelial dysfunction is a common denominator.
Perspectives
Although our knowledge on S1P has substantially increased in the recent years, the regulation and function of S1P signaling in BP homeostasis, and in other cardiovascular diseases, remain largely unknown. Our study reveals an important role of S1P signaling in the pathogenesis of hypertension and establishes the foundation for therapeutic intervention on the S1PR1 signaling pathway. A better understanding of the role of S1P signaling in cardiovascular diseases has the potential to be rapidly translated, especially considering that this pathway is already therapeutically targeted in autoimmune diseases.
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